Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9862598 | 0.91 | KDM4C (0.49) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL4079349 | 0.88 | KDM4C (0.49) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL4078714 | 0.88 | KDM4C (0.49) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL7272362 | 0.85 | KDM4C (0.49) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL9082916 | 0.85 | KDM4C (0.49) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL1003115 | 0.85 | KDM4C (0.49) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL14228817 | 0.85 | KDM4C (0.49) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL13953673 | 0.85 | KDM4C (0.49) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL5429878 | 0.85 | KDM4C (0.49) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL1422310 | 0.85 | KDM4C (0.49) | KDM4CL3MBTL1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
| US-5476846-A | Administering anti-thrombotic and anti-asthmatic agent | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1995-12-19 | — | — | US | disclosed |
| EP-0472449-B1 | Substituted sulfonamides, processes for their preparation and medicines containing them | LIPHA (FR) | 1994-09-14 | — | — | EP | disclosed |
| EP-0472449-A2 | Substituted sulfonamides, processes for their preparation and medicines containing them | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1992-02-26 | — | — | EP | disclosed |
| US-5021414-A | Antiestrogen | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-06-04 | — | — | US | disclosed |
| US-4904661-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-02-27 | — | — | US | disclosed |
| US-4732912-A | ANTIESTROGENS, ANTITUMOR AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-22 | — | — | US | disclosed |
| EP-0124369-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-06-24 | — | — | EP | disclosed |
| EP-0124369-A1 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | KDM4C 480/4885L3MBTL1 4871/4885NPC1 2753/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | KDM4C 480/4885L3MBTL1 4871/4885NPC1 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.